^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF8 overexpression

    i
    Other names: TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
    Entrez ID:
    943
    Related biomarkers:
    Expression
    Others
    1year
    Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. (PubMed, JAMA Dermatol)
    Posttreatment biopsies showed complete clearance of the LR in all patients. This study found that dupilumab treatment can cause a reversible and benign LR, which mimics a CTCL, though has distinctive histopathologic features.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CD2 (CD2 Molecule)
    |
    TNFRSF8 expression • TNFRSF8 overexpression
    |
    Dupixent (dupilumab)
    1year
    One Tube 23 Color Full Spectral Flow Cytometry Panel in Detecting Minimal Residual Disease in Pediatric B-Cell Acute Lymphoblastic Leukemia (ASH 2023)
    Results The limit of blank (LOB), limit of detection (LOD), and lower limit of quantitation (LLOQ) were firstly determined, the results showed reproducible sensitivity up to 0.001% (1-in-105) after acquisition of 4.8 million cells for 23-color panel...Conclusion Based on these evidences, SMFC-based one-tube 23-color MRD panel for B-ALL was convenient and maneuverable with higher sensitivity and specificity compared to conventional 8-color FC-MRD panel. It would be a promising method to improve the risk stratification.
    Clinical • IO biomarker • Minimal residual disease
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD73 (5'-Nucleotidase Ecto) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • CD44 (CD44 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD200 (CD200 Molecule) • CD24 (CD24 Molecule) • MME (Membrane Metalloendopeptidase) • CD58 (CD58 Molecule) • CEACAM6 (CEA Cell Adhesion Molecule 6) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NRP1 (Neuropilin 1) • ANPEP (Alanyl Aminopeptidase, Membrane) • CD81 (CD81 Molecule) • CD86 (CD86 Molecule)
    |
    CD73 overexpression • CD44 expression • TNFRSF8 overexpression
    over1year
    Guttate psoriasis in a patient with Cutaneous T-cell Lymphoma in treatment with Brentuximab vedotin: an unreported association (WCD 2023)
    On the contrary, blockade of CD30L/CD30 signaling significantly promoted the expression of cytokines involved in psoriasis development. In accordance with the evidence displayed by these in vivo animal models, a similar bio-pathological mechanism may be responsible for BV-induced psoriasis in humans
    Clinical
    |
    CD4 (CD4 Molecule) • IL17A (Interleukin 17A) • IL22 (Interleukin 22)
    |
    TNFRSF8 expression • TNFRSF8 overexpression
    |
    Adcetris (brentuximab vedotin)
    over1year
    CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia/Lymphoma. (PubMed, Int J Mol Sci)
    Successful anti-CD30 antibody-drug conjugate (ADC) therapy for HL, ALCL, and PTCL supports the biological significance of CD30 in these lymphomas. In this review, we discuss the roles of CD30 overexpression and its functions during ATL progression.
    Review • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    TNFRSF8 expression • TNFRSF8 overexpression
    over1year
    RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types. (ASCO 2023)
    In order to target HER2, systemic treatment was changed to a combination containing trastuzumab and pertuzumab, resulting in pathological complete response...Staining showed high PDL-1 (CPS50), prompting a change in therapy to an anti-PDL-1 (pembrolizumab) therapy... RNA-seq is emerging as an objective tool to evaluate key diagnostic and targetable events in multiple cancer types. The use of RNA-seq can also add value as an objective measurement to confirm critical IHC findings, potentially changing clinical care.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    PD-L1 expression • HER-2 positive • PD-L1 overexpression • HER-2 negative • HER-2 expression • TNFRSF8 positive • TNFRSF8 expression • HER-2 amplification + PD-L1 expression • TNFRSF8 negative • TNFRSF8 overexpression
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • BostonGene Tumor Portrait™ Test
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost2years
    Breast MALT Lymphoma: A Clinical, Histomorphologic, and Immunophenotypic Evaluation. (PubMed, Int J Surg Pathol)
    Having increased IgG- and IgG4-positive cells with a high IgG/IgG4 ratio in breast MALT lymphoma may indicate cutaneous origin. CD30 overexpression may be a feature seen in marginal zone lymphoma of cutaneous origin, which needs further studies to prove.
    Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 positive • TNFRSF8 expression • TNFRSF8 overexpression